<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04727229</url>
  </required_header>
  <id_info>
    <org_study_id>20-301</org_study_id>
    <nct_id>NCT04727229</nct_id>
  </id_info>
  <brief_title>Stellate Ganglion Block for Major Depressive Disorder.</brief_title>
  <official_title>Stellate Ganglion Block for Major Depressive Disorder: A Randomized Controlled Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karim Ladha</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Unity Health Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Unity Health Toronto</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a feasibility study, to investigate a new treatment option for major depressive&#xD;
      disorders by performing a Stellate Ganglion Block (SGB). A SGB is an injection of local&#xD;
      anesthetic into the sympathetic nervous system (peripheral nervous system) located in the&#xD;
      lower part of the neck, to relieve pain in the head, neck, upper arm, and upper chest.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 23, 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility, Recruitment, Acceptability, Safety,</measure>
    <time_frame>1 year</time_frame>
    <description>Recruitment rate, withdrawal rate, adherence rate, frequency of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the symptoms of depression</measure>
    <time_frame>6 weeks</time_frame>
    <description>≥ 50% reduction in the Montgomery-Åsberg Depression Rating Scale (MADRS) score. The MADRS score range from 0 to 6 = no depression; from 7 to 19 = mild depression, 20 to 34 = moderate depression, 35 and greater = severe depression, and a total score of 60 or greater = very severe depression</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Treatment Resistant Depression</condition>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Bupivacaine Hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of Bupivacaine Hydrochloride 0.5% near the stellate ganglion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline Solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Injection of Normal Saline near the stellate ganglion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine Hydrochloride</intervention_name>
    <description>Injection of Bupivacaine near the stellate ganglion</description>
    <arm_group_label>Bupivacaine Hydrochloride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Injection of Normal Saline near the stellate ganglion</description>
    <arm_group_label>Normal Saline Solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 - 65 years of age&#xD;
&#xD;
          2. Major depressive disorder without psychotic symptoms according to DSM-5 criteria&#xD;
&#xD;
          3. Hamilton Depression Rating Scale (HAMD)&gt;17&#xD;
&#xD;
          4. Current major depressive episode as confirmed by the Mini International&#xD;
             Neuropsychiatric Interview (MINI)&#xD;
&#xD;
          5. Failure of at least two trials of antidepressant therapy during the current episode&#xD;
&#xD;
          6. Capacity to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Depression secondary to stroke, cancer or other severe medical illness&#xD;
&#xD;
          2. Major Depressive Episode in people with Bipolar Disorder.&#xD;
&#xD;
          3. Dementia&#xD;
&#xD;
          4. Post-Traumatic Stress Disorder (PTSD)&#xD;
&#xD;
          5. Acute suicidality defined as score ≥3 on HAMD item 3&#xD;
&#xD;
          6. Previous electroconvulsive therapy&#xD;
&#xD;
          7. Known history of intolerance of hypersensitivity to local anesthetic&#xD;
&#xD;
          8. Current substance abuse or dependence (except for caffeine or nicotine dependence)&#xD;
             and/or recent history (last 12 months) of current alcohol abuse or dependence, as&#xD;
             defined in DSM-5 criteria&#xD;
&#xD;
          9. Unwilling to maintain current antidepressant regimen.&#xD;
&#xD;
         10. A clinical finding/condition that is unstable or that, in the opinion of the&#xD;
             investigator(s) would negatively be affected by an SGB (e.g. movement disorder where&#xD;
             patient is unable to lie still for injection or anatomical variants making an SGB&#xD;
             impractical).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karim Ladha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unity Health Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karim Ladha, MD</last_name>
    <phone>416-864-5825</phone>
    <email>karim.ladha@mail.utoronto.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Janneth Pazmino-Canizares, MSc</last_name>
    <phone>416-884-6060</phone>
    <phone_ext>49561</phone_ext>
    <email>Janneth.Pazmino-Canizares@unityhealth.to</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karim Ladha, MD</last_name>
      <phone>416-864-5825</phone>
      <email>karim.ladha@utoronto.ca</email>
    </contact>
    <contact_backup>
      <last_name>Janneth Pazmino-Canizares, MSc</last_name>
      <phone>416-864-6060</phone>
      <phone_ext>49561</phone_ext>
      <email>Janneth.Pazmino-Canizares@unityhealth.to</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 22, 2021</study_first_submitted>
  <study_first_submitted_qc>January 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Unity Health Toronto</investigator_affiliation>
    <investigator_full_name>Karim Ladha</investigator_full_name>
    <investigator_title>Associate Scientist. Staff Physicial</investigator_title>
  </responsible_party>
  <keyword>Feasibility trial</keyword>
  <keyword>Stellate Ganglion Block</keyword>
  <keyword>Bupivacaine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ganglion Cysts</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No individual participant data has been planned to be shared with other researchers at this point since this is a feasibility study with only 10 participants.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

